FTIH of ECC5004 in Healthy and Diabetic Participants

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus

Timeline

Start

2022-12-01

Primary completion

2023-11-01

Completion

2023-11-01

Publications

• Haggag AZ, Xu J, Butcher L, Pagnussat S, Davies G, Lundqvist S, Wang W, Van Zuydam N, Nelander K, Jha A, Yu H, Boianelli A, Lindmark B, Ollerstam A, Sun X, Wang F, Pan X, Liu H, Chen W, Xu J, Wallenius K, Zhou J. Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist. Diabetes Obes Metab. 2025 Feb;27(2):551-562. doi: 10.1111/dom.16047. Epub 2024 Nov 4.

Drugs

Indications